No Data
No Data
Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Reported, And Analysts Assigned A US$394 Price Target
Last week saw the newest quarterly earnings release from Bio-Rad Laboratories, Inc. (NYSE:BIO), an important milestone in the company's journey to build a stronger business. The analysts typi
Bio-Rad Laboratories | 10-Q: Quarterly report
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating
Bio-Rad Laboratories (BIO) has an average outperform rating and price target range of $365 to $441, according to analysts polled by Capital IQ. Price: 271.46, Change: -8.45, Percent Change: -3.02
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS
Bio-Rad Laboratories Price Target Cut to $385.00/Share From $420.00 by UBS
Bio-Rad Laboratories Is Maintained at Buy by UBS
Bio-Rad Laboratories Is Maintained at Buy by UBS